JP6333271B2 - ＩＬ−１βへの結合メンバー - Google Patents

ＩＬ−１βへの結合メンバー Download PDF

Info

Publication number
JP6333271B2
JP6333271B2 JP2015540154A JP2015540154A JP6333271B2 JP 6333271 B2 JP6333271 B2 JP 6333271B2 JP 2015540154 A JP2015540154 A JP 2015540154A JP 2015540154 A JP2015540154 A JP 2015540154A JP 6333271 B2 JP6333271 B2 JP 6333271B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr
composition
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015540154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503293A5 (pt
JP2016503293A (ja
Inventor
ステファニー グラブロフスキー，
ステファニー グラブロフスキー，
タイタス クレッチマー，
タイタス クレッチマー，
シモン シュミット，
シモン シュミット，
アブディジャパール シャムシエブ，
アブディジャパール シャムシエブ，
トルステン アレクサンダー シェーファー，
トルステン アレクサンダー シェーファー，
Original Assignee
セル メディカ スイッツァランド アーゲー
セル メディカ スイッツァランド アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル メディカ スイッツァランド アーゲー, セル メディカ スイッツァランド アーゲー filed Critical セル メディカ スイッツァランド アーゲー
Publication of JP2016503293A publication Critical patent/JP2016503293A/ja
Publication of JP2016503293A5 publication Critical patent/JP2016503293A5/ja
Application granted granted Critical
Publication of JP6333271B2 publication Critical patent/JP6333271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
JP2015540154A 2012-11-05 2013-11-05 ＩＬ−１βへの結合メンバー Active JP6333271B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722532P 2012-11-05 2012-11-05
EP12007503 2012-11-05
EP12007503.1 2012-11-05
US61/722,532 2012-11-05
PCT/EP2013/073009 WO2014068132A1 (en) 2012-11-05 2013-11-05 Binding members to il-1 beta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018083160A Division JP6779252B2 (ja) 2012-11-05 2018-04-24 ＩＬ−１βへの結合メンバー

Publications (3)

Publication Number Publication Date
JP2016503293A JP2016503293A (ja) 2016-02-04
JP2016503293A5 JP2016503293A5 (pt) 2016-12-08
JP6333271B2 true JP6333271B2 (ja) 2018-06-06

Family

ID=47146146

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540154A Active JP6333271B2 (ja) 2012-11-05 2013-11-05 ＩＬ−１βへの結合メンバー
JP2018083160A Active JP6779252B2 (ja) 2012-11-05 2018-04-24 ＩＬ−１βへの結合メンバー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018083160A Active JP6779252B2 (ja) 2012-11-05 2018-04-24 ＩＬ−１βへの結合メンバー

Country Status (12)

Country Link
US (5) US9404930B2 (pt)
EP (2) EP2914287B1 (pt)
JP (2) JP6333271B2 (pt)
KR (1) KR102345999B1 (pt)
CN (1) CN104870015B (pt)
BR (1) BR112015009892B1 (pt)
CA (1) CA2888583C (pt)
HK (1) HK1214150A1 (pt)
MX (1) MX2015005384A (pt)
PL (1) PL2914287T3 (pt)
RU (1) RU2711118C2 (pt)
WO (2) WO2014068132A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404930B2 (en) * 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta
US9078427B1 (en) 2014-08-29 2015-07-14 Pioneer Hi Bred International Inc Method of storing plant embryos
CA2954981C (en) 2014-08-29 2023-01-03 Pioneer Hi-Bred International, Inc. Methods and devices involving oil matrices
JP6202652B1 (ja) * 2016-12-19 2017-09-27 株式会社ヘルスケアシステムズ 抗エクオール抗体組成物及びその利用
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US20220161243A1 (en) 2019-02-28 2022-05-26 Exxonmobil Chemical Patents Inc. Catalyst Compositions and Precursors, Processes for Making the Same and Syngas Conversion Processes
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116068192A (zh) * 2022-01-24 2023-05-05 中国农业大学 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
HUE048922T2 (hu) 2002-05-22 2020-09-28 Novartis Ag Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
AU2006208286A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
PL1899378T3 (pl) * 2005-06-21 2011-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
GB2461273A (en) 2008-06-24 2009-12-30 Seppo Haekkinen Load monitoring system
GB0811574D0 (en) 2008-06-24 2008-07-30 Trillion Genomics Ltd Characterising planar samples by mass spectrometry
DK3241843T3 (da) 2008-06-25 2021-09-06 Novartis Ag Opløselighedsoptimering af immunbindere
KR101882352B1 (ko) 2008-06-25 2018-07-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
EP2341935A4 (en) * 2008-09-05 2012-07-25 Xoma Technology Ltd METHODS FOR IMPROVING BETA CELL FUNCTION
RU2013115927A (ru) * 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
US9404930B2 (en) * 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta

Also Published As

Publication number Publication date
CA2888583A1 (en) 2014-05-08
EP2914287A1 (en) 2015-09-09
US20170051054A1 (en) 2017-02-23
US20180362642A1 (en) 2018-12-20
WO2014068132A1 (en) 2014-05-08
KR102345999B1 (ko) 2021-12-30
US11267884B2 (en) 2022-03-08
BR112015009892B1 (pt) 2022-12-27
PL2914287T3 (pl) 2020-09-07
MX2015005384A (es) 2015-10-09
KR20150079753A (ko) 2015-07-08
US10626171B2 (en) 2020-04-21
CN104870015B (zh) 2019-07-30
US20220220195A1 (en) 2022-07-14
EP3750917A1 (en) 2020-12-16
EP2914287B1 (en) 2020-03-18
CA2888583C (en) 2022-03-29
RU2015120450A (ru) 2016-12-27
US20140134183A1 (en) 2014-05-15
WO2015067636A1 (en) 2015-05-14
HK1214150A1 (zh) 2016-07-22
JP6779252B2 (ja) 2020-11-04
JP2018113988A (ja) 2018-07-26
JP2016503293A (ja) 2016-02-04
CN104870015A (zh) 2015-08-26
US20200239565A1 (en) 2020-07-30
US9404930B2 (en) 2016-08-02
RU2711118C2 (ru) 2020-01-15
BR112015009892A2 (pt) 2017-08-22
US10077302B2 (en) 2018-09-18

Similar Documents

Publication Publication Date Title
JP6779252B2 (ja) ＩＬ−１βへの結合メンバー
US11407824B2 (en) Nucleic acids encoding antibodies against IL-1 beta
KR102653724B1 (ko) 개선된 혈청 알부민 결합제
US20230060574A1 (en) Serum albumin binders
US20210332119A1 (en) Binding members to tnf alpha
CN112851805A (zh) 一种结合血清白蛋白的蛋白及其用途
WO2013103783A1 (en) Murine il-13 antibodies
ES2795829T3 (es) Miembros de unión a IL-1 beta
KR102662499B1 (ko) 개선된 혈청 알부민 결합제
RU2789495C2 (ru) Усовершенствованные связывающиеся с сывороточным альбумином вещества
GRABULOVSKI et al. Patent 2888583 Summary

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180322

R155 Notification before disposition of declining of application

Free format text: JAPANESE INTERMEDIATE CODE: R155

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180424

R150 Certificate of patent or registration of utility model

Ref document number: 6333271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250